US House Rejects Substitute Patent Bill
A substitute patent bill that would have nullified key provisions of abill to overhaul the US patent system has been rejected by the House of Representatives.
The substitute bill, defeated by a 227 to 178 vote, would have prevented Congress from changing the Patent and Trademark Office into a government-owned corporation, and also from altering the current patent system so that all patent applications would be published 18 months after they had been filed.
The main bill, HR 400 (see also page 13), is supported by the Clinton Administration and would bring US patent law into line with that of Europe and Japan. Final action on HR 400 is expected soon; it must still be considered by the Senate.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze